Skip to main
IRON
IRON logo

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc. is positioned favorably for growth, evidenced by a significant 214% increase in erythropoietic protoporphyria (EPP) prevalence estimates over the past 15 years, coupled with an annual growth rate of approximately 8%. The promising results from the BEACON and AURORA trials highlight the efficacy of bitopertin in achieving substantial reductions in protoporphyrin IX (PPIX), which correlates with improved patient outcomes, particularly in sunlight tolerance and phototoxic reactions. Additionally, the ongoing developments for treatments targeting anemia of myelofibrosis and chronic kidney disease, along with potential advancements in discussions with the European Medicines Agency, underscore the robust clinical pipeline that may enhance the company's market position and financial prospects.

Bears say

Disc Medicine Inc's negative outlook is influenced by several fundamental risks associated with its clinical pipeline and market positioning. The company faces significant challenges related to achieving clinical requirements, which could undermine projected sales estimates and hinder revenue generation, especially if reimbursement for its therapies is not secured. Additionally, the presence of competitors with potentially better pricing strategies and a greater market penetration may limit Disc Medicine's sales potential, especially with its flagship product, bitopertin, amidst a misalignment in patient diagnosis estimates that could affect market size.

IRON has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 11 analysts, IRON has a Buy consensus rating as of Jul 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.